Yazar "Gorgel, Ahmet" seçeneğine göre listele

Listeleniyor 1 - 7 / 7
  • Küçük Resim
    Öğe
    Autoimmune polyglandular syndrome type III which accompanies to multiple sclerosis: A case report
    (2019) Gorgel, Ahmet; Tecellioglu, Mehmet; Cankaya, Cem
    Autoimmune polyglandular syndrome type III (APS III) is characterised by autoimmune destruction of various endocrine and nonendocrine tissues. It differs from APS I and APS II in terms of without adrenal involvement. Although APS III includes a series of autoimmune disorders, it is rarely associated with multiple sclerosis (MS). A 41-year-old female patient had diplopia, visual blurring, dizziness, and giddiness for 2 weeks. In her medical history, she had a diagnosis of MS and using Teriflunomide. It was detected positivity of antinuclear antibody (ANA), anti-thyroid peroxidase (Anti-TPO) and anti-thyroglobulin (Anti-TG) antibodies. Based on these results, the patient with MS who has chronic autoimmune thyroiditis and primary ovarian failure was diagnosed with APS III. The coexistence of APS-III and MS is a rare clinical entity. Moreover, hypothyroidism has been detected during teriflunomide therapy in the patient. Hypothyroidism was most likely a component of APS-III in our case, but it may also have been triggered by teriflunomide.
  • Küçük Resim
    Öğe
    Autoimmune polyglandular syndrome type III which accompanies to multiple sclerosis: A case report
    (2019) Gorgel, Ahmet; Tecellioğlu, Mehmet; Çankaya, Cem
    Abstract: Autoimmune polyglandular syndrome type III (APS III) is characterised by autoimmune destruction of various endocrine and nonendocrine tissues. It differs from APS I and APS II in terms of without adrenal involvement. Although APS III includes a series ofautoimmune disorders, it is rarely associated with multiple sclerosis (MS). A 41-year-old female patient had diplopia, visual blurring,dizziness, and giddiness for 2 weeks. In her medical history, she had a diagnosis of MS and using Teriflunomide. It was detectedpositivity of antinuclear antibody (ANA), anti-thyroid peroxidase (Anti-TPO) and anti-thyroglobulin (Anti-TG) antibodies. Based onthese results, the patient with MS who has chronic autoimmune thyroiditis and primary ovarian failure was diagnosed with APSIII. The coexistence of APS-III and MS is a rare clinical entity. Moreover, hypothyroidism has been detected during teriflunomidetherapy in the patient. Hypothyroidism was most likely a component of APS-III in our case, but it may also have been triggered byteriflunomide.
  • Küçük Resim Yok
    Öğe
    Coexistence of pituitary incidentaloma and primary hyperparathyroidism mimicking multiple endocrine neoplasia Type 1: A case report
    (2021) Gorgel, Ahmet; Tecellioglu, Mehmet; Cankaya, Cem
    The widespread use of imaging procedures has led to an increased discovery of incidental masses in the pituitary gland. Although the majority of pituitary incidentalomas are non-functioning benign adenomas but their increased prevalence poses a diagnostic and therapeutic challenge. These masses may cause various hormonal disturbances as well as they might also be a component of multiple endocrine neoplasia syndromes type 1 (MEN-1) or type 4 (MEN-4). In both syndromes, primary hyperparathyroidism frequently accompanies with pituitary adenomas. Herein we present a 56-year-old man with pituitary incidentaloma who is also detected primary hyperparathyroidism. Contrary to our expectations, any gene defects could be found related with neither MEN-1 nor MEN-4 in the genetic examinatio
  • Küçük Resim
    Öğe
    Coexistence of pituitary incidentaloma and primary hyperparathyroidism mimicking multiple endocrine neoplasia Type 1: A case report
    (2021) Gorgel, Ahmet; Tecellioglu, Mehmet; Cankaya, Cem
    The widespread use of imaging procedures has led to an increased discovery of incidental masses in the pituitary gland. Although the majority of pituitary incidentalomas are non-functioning benign adenomas but their increased prevalence poses a diagnostic and therapeutic challenge. These masses may cause various hormonal disturbances as well as they might also be a component of multiple endocrine neoplasia syndromes type 1 (MEN-1) or type 4 (MEN-4). In both syndromes, primary hyperparathyroidism frequently accompanies with pituitary adenomas. Herein we present a 56-year-old man with pituitary incidentaloma who is also detected primary hyperparathyroidism. Contrary to our expectations, any gene defects could be found related with neither MEN-1 nor MEN-4 in the genetic examination.
  • Küçük Resim Yok
    Öğe
    EFFECTS OF RENAL REPLACEMENT THERAPY ON FIBROMYALGIA SYNDROME IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    (Carbone Editore, 2018) Berber, Ilhami; Sahin, Idris; Gorgel, Ahmet; Cagin, Yasir Furkan; Bag, Harika Gozukara; Berber, Nurcan Kirici
    Introduction: Although musculoskeletal disorders are among the major complications of chronic kidney disease (CKD), there are scarce data to investigate fibromyalgia syndrome (FMS) in these patients. We aimed to investigate the prevalence of FMS in the patients with CKD. Material and methods: A total of 289 (119 predialysis (PD), 85 hemodialysis (HD), 85 continuous ambulatory peritoneal dialysis (CAPD)) patients were included. Diagnosis of FMS was based on American College of Rheumatology (ACR) 1990 FMS criteria. Results: Mean age was 52 +/- 16 years (range 18-89 years). One-hundred-sixty-four (56.7%) of them were male. A total of 46 patients (10 male/36 female) (15.9%) were diagnosed FMS. The prevalence of FMS was 28.8% in females and 6.1% in males. Compared to males, females had a significantly higher rate of FMS (p<0.001). The prevalence of FMS was 19.3% in PD group, 17.6% in the CAPD group, and 9.4% in the HD group. Although the frequency of FMS was lower in HD group compared to both the PD and the CAPD groups, the differences were not statistically significant (for HD vs PD, p=0.052; for HD vs CAPD, p=0.113). In PD group, hemoglobin (Hb) levels were significantly higher in patients with FMS than without FMS. Parathormone (PTH) levels were significantly lower in CAPD patients with FMS than without FMS. Although the prevalence of FMS was increased in PD and CAPD patients, this increase did not reach statistical significance. FMS was markedly more prevalent in female patients. While the Hb level was lower in the PD patients with FMS, PTH level was lower in the CAPD patients diagnosed with FMS. Conclusions: Our study demonstrated that the rate of FMS was higher in PD and CAPD patients compared to HD patients, although our results did not reach statistical significance. Among the entire demographic and laboratory parameters, female gender was found to be significant risk factor for development of FMS. Future multicenter studies which have large sample size are clearly needed to determine other factors related to development of FMS in patients with CKD.
  • Küçük Resim Yok
    Öğe
    Tamsulosin-induced Hyperprolactinemia in a Patient with Multiple Sclerosis: A Case Report
    (Galenos Publ House, 2019) Gorgel, Ahmet; Soylu, Ahmet; Gorgel, Sacit; Tecellioglu, Mehmet; Sarier, Mehmet
    Drug-induced hyperprolactinemia is one of the most common causes of non-physiologic hyperprolactinemia. In contrary to other anterior pituitary hormones, prolactin is not controlled via hypothalamic-pituitary negative feedback mechanism. Since prolactin secretion is inhibited mainly by dopamine, some drugs such as antipsychotics and prokinetics which block dopamine receptors may lead to hyperprolactinemia. Nevertheless, despite this well-known phenomenon, most of cases of drug-induced hyperprolactinemia are asymptomatic. On the other hand, hyperprolactinemia due to tamsulosin that is an alpha adrenergic receptor antagonist has not been reported yet. Herein, we present a 39-year-old woman with multiple sclerosis who developed hyperprolactinemia after starting treatment with tamsulosin for neurogenic bladder disease.
  • Küçük Resim
    Öğe
    Tamsulosin-induced hyperprolactinemia in a patient with multiple sclerosis: a case report
    (Journal of urologıcal surgery, 2018) Gorgel, Ahmet; Soylu, Ahmet; Gorgel, Sacit; Tecellioglu, Mehmet
    Drug-induced hyperprolactinemia is one of the most common causes of non-physiologic hyperprolactinemia. In contrary to other anterior pituitary hormones, prolactin is not controlled via hypothalamic-pituitary negative feedback mechanism. Since prolactin secretion is inhibited mainly by dopamine, some drugs such as antipsychotics and prokinetics which block dopamine receptors may lead to hyperprolactinemia. Nevertheless, despite this well-known phenomenon, most of cases of drug-induced hyperprolactinemia are asymptomatic. On the other hand, hyperprolactinemia due to tamsulosin that is an alpha adrenergic receptor antagonist has not been reported yet. Herein, we present a 39-year-old woman with multiple sclerosis who developed hyperprolactinemia after starting treatment with tamsulosin for neurogenic bladder disease.